Pure Global AI
NCT05880355Not yet recruiting

Advanced Cardiovascular Imaging of the Systemic Effects of Inflammasome Activation

University of VirginiaPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Myocardial Infarction
Drug/Device/Intervention
Dapansutrile
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
University of Virginia
Location
Charlottesville, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Jan 01, 2024
End date
Oct 30, 2028
Enrollment
60 participants
Primary outcome

Remote plaque volume

Summary

Subjects with urgently reperfused type I myocardial infarction (MI) will be recruited and
 randomized to receive either placebo or the oral inflammasome (NLRP3) inhibitor dapansutrile.
 The primarily outcome measure will be carotid plaque volume change over 6 months; secondary
 outcome measures will be plaque inflammatory activity and coronary microvascular function.

ICD-10 classifications
Acute myocardial infarctionAcute myocardial infarction, unspecifiedOld myocardial infarctionSubsequent myocardial infarctionObservation for suspected myocardial infarction
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05880355
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05880355 through Pure Global AI's free database. This Phase 1 trial is sponsored by University of Virginia and is currently Not yet recruiting. The study focuses on Myocardial Infarction. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.